Fidelity, Arch back precision medicine startup’s $178M round

Precision medicine startup FogPharma has raised $178 million as it prepares to launch its first human trial within the next year.

With the help of the Series C, FogPharma plans to launch a Phase 1 clinical trial of its lead drug in mid-2023. The drug is a protein therapeutic — specifically, a stabilized polypeptide made of alpha-helix structures — that could be applicable in "a broad range of intractable cancers," according to a statement.

The Cambridge company disclosed the Series D round…

Previous As inflation continues, here's how the San Francisco region ranks for affordability
Next Pearlridge Center set to welcome new retailers